HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
2-iodobenzoic acid
RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4891
Also Known As:
2-iodobenzoic acid, 123I-labeled; 2-iodobenzoic acid, 125I-labeled; 2-iodobenzoic acid, 131I-labeled; 2-iodobenzoic acid, monosodium salt; 2-iodobenzoic acid, monosodium salt, 131I-labeled; 2-iodobenzoic acid, potassium salt; 2-iodobenzoic-(125)I acid; OISB; Progonasyl; o-iodobenzoic-(125)I acid; ortho-iodo-sodium benzoate; sodium 2-iodobenzoate
Networked:
6
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Benzoates: 426
Iodobenzoates
2-iodobenzoic acid: 6
Carboxylic Acids: 973
Carbocyclic Acids
Benzoates: 426
Iodobenzoates
2-iodobenzoic acid: 6
Related Diseases
1.
Myocardial Ischemia (Ischemic Heart Diseases)
10/01/1977 - "
Furthermore, a 5-minute intracoronary infusion of OISB (200 mg/min) during myocardial ischemia produced an increase in O2E, MVO2 and myocardial contractility with little change in coronary venous pO2.
"
05/01/1983 - "
Effects of ortho-iodo sodium benzoate on acute myocardial ischemia, hemodynamic function, and infarct size after coronary artery occlusion in dogs.
"
05/01/1983 - "
Protocol III studies assessed the effects of OISB on cardiac hemodynamic function and acute myocardial ischemic damage when infusion was begun 15 minutes after LAD occlusion: average epicardial S-T segment elevation was not altered by saline solution, but decreased when OISB was infused during the last 15 minutes of myocardial ischemia.
"
2.
Coronary Occlusion
05/01/1983 - "
OISB also reduces myocardial ischemic injury when its administration is begun 15 minutes after coronary occlusion, while effecting decreases in heart rate, left ventricular contractility, and cardiac output.
"
05/01/1983 - "
Reductions in heart rate, left ventricular dP/dt, and cardiac output were observed in 7 dogs during OISB infusion, but there were no changes in these measurements during coronary occlusion in 5 dogs receiving a constant infusion of saline solution.
"
05/01/1983 - "
In Protocol I studies (n = 9), preocclusion intravenous infusion of OISB (500 mg/kg) reduced epicardial S-T segment elevation 15 minutes after coronary occlusion, while a similar volume of normal saline solution did not affect this index of ischemic damage.
"
3.
Hypoxia (Hypoxemia)
04/01/1979 - "
Hypoxemia-induced lactatemia was greatest with a high P50 (OISB).
"
06/01/1977 - "
In spite of significant hypoxemia, hematocrit rose only slightly during the period of OISB infusion.
"
11/01/1984 - "
Mean survival time was prolonged from 67.8 (control saline) to 94.8 sec (OISB 300 mg/kg) and 112.2 sec (OISB 600 mg/kg) in the hypobaric hypoxia, and from 201.3 sec (control saline) to 329.7 sec (OISB 300 mg/kg) and 407.7 sec (OISB 600 mg/kg) in the carbon monoxide hypoxia.
"
06/01/1977 - "
Hypoxemia caused an increase of this metabolite from 0.91 +/- 0.21 to 1.50 +/- 0.28 moles/moles of hemoglobin (p less than 0.05); the rise was not as great as that observed in hypoxemic dogs without OISB treatment.
"
4.
Hemorrhagic Shock
02/01/1991 - "
Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) rose in prolonged hemorrhagic shock in the control group and conversely decreased in OISB-treated dogs.
"
02/01/1991 - "
Sodium o-iodobenzoate (OISB) produces an increase in P50 (PO2 at 50% of oxyhemoglobin saturation) and survival when infused at the time of initiation of prolonged hemorrhagic shock in dogs.
"
5.
Polycythemia (Erythrocytosis)
06/01/1977 - "
OISB increased P50 and prevented the compensatory polycythemia regularly seen when dogs are made hypoxemic.
"
Related Drugs and Biologics
1.
Solutions
2.
Saline Solution
3.
2,3-Diphosphoglycerate (2,3 Bisphosphoglycerate)
4.
Sodium
5.
Oxyhemoglobins (Oxyhemoglobin)
6.
Carbon Monoxide
7.
hemoglobin P (Hb P)
Related Therapies and Procedures
1.
Intravenous Infusions